Table 4 Univariate analysis of the correlation between vasoactive peptides and clinical characteristics

Age (years)

  0–6

40.65 ± 7.74

102.44 ± 13.35

  6–12

40.82 ± 4.79

106.25 ± 14.10

  12–18

42.33 ± 5.05

106.82 ± 11.48

Gender

  Man

42.07 ± 4.71

106.65 ± 10.71

  Women

40.69 ± 6.06

104.98 ± 14.79

Course (months)

  0–6

42.33 ± 5.04

106.82 ± 11.48

  6–12

40.38 ± 5.43

104.11 ± 13.57

  12–18

42.27 ± 4.33

111.38 ± 11.86

  18–24

33.03 ± 3.79

104.43 ± 10.56

  > 24

46.23 ± 3.42

108.74 ± 7.39

Duration attacks (hours)

  0–2

41.82 ± 4.81

105.91 ± 13.04

  2–4

39.32 ± 5.46

102.46 ± 13.25

  4–6

43.43 ± 3.22

109.08 ± 5.93

  > 6

42.31 ± 5.50

105.16 ± 9.13

VAS score

  0–3

46.18 ± 3.75

110.87 ± 7.39

  4–6

41.93 ± 6.82

105.15 ± 17.25

  7–10

40.75 ± 5.23

105.94 ± 10.84

Frequency (times/month)

  0–15

45.04 ± 3.82

113.63 ± 14.16

  15–30

42.07 ± 4.87

107.89 ± 12.44

  30–60

40.36 ± 4.18

100.42 ± 11.23

 Visual aura

40.10 ± 6.84

108.32 ± 13.36

 Sensory aura

41.01 ± 4.84

103.29 ± 13.34

 Motor aura

38.90 ± 5.13

102.56 ± 15.90

 Nausea

40.94 ± 6.23

109.28 ± 12.55

 Vomiting

43.49 ± 4.68

107.57 ± 13.42

 Photophobia

43.03 ± 7.57

107.75 ± 15.72

 Phonophobia

42.04 ± 8.75

104.04 ± 15.12

 Dizziness

40.97 ± 5.98

107.42 ± 13.38

 Ophthalmalgia

41.51 ± 4.50

109.30 ± 5.73

 Abdominal pain

39.14 ± 6.70

102.85 ± 13.17

 Unilateral temporal

41.85 ± 4.93

105.91 ± 11.35

 Bilateral temporal

42.41 ± 3.94

112.43 ± 12.64

 Frontal

40.49 ± 6.28

103.97 ± 13.56

 Parietal

40.03 ± 4.42

104.48 ± 11.86

 Occipital

42.18 ± 5.03

107.20 ± 10.26